Similar articles for PMID: 10580197

Year	Number of Results
1989	1
1992	7
1993	4
1994	9
1995	9
1996	4
1997	8
1998	4
1999	11
2000	7
2001	10
2002	11
2003	4
2004	4
2005	4
2006	4
2007	3
2008	1
2010	1
2012	1
2014	1
2015	2
2016	1
2017	2
2020	1
2024	0

1

Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies.

Gorse GJ, Patel GB, Mandava MD, Belshe RB. Gorse GJ, et al. Vaccine. 1999 Dec 10;18(9-10):835-49. doi: 10.1016/s0264-410x(99)00323-0. Vaccine. 1999. PMID: 10580197 Clinical Trial.

2

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

AIDS Vaccine Evaluation Group 022 Protocol Team. AIDS Vaccine Evaluation Group 022 Protocol Team. J Infect Dis. 2001 Feb 15;183(4):563-70. doi: 10.1086/318523. Epub 2001 Jan 18. J Infect Dis. 2001. PMID: 11170981 Clinical Trial.

3

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.

Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, Graham BS, McElrath MJ, Clements-Mann ML, Mulligan MJ, Fast P, Walker MC, Excler JL, Duliege AM, Tartaglia J. Evans TG, et al. J Infect Dis. 1999 Aug;180(2):290-8. doi: 10.1086/314895. J Infect Dis. 1999. PMID: 10395842 Clinical Trial.

4

Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.

Johnson RP, Hammond SA, Trocha A, Siliciano RF, Walker BD. Johnson RP, et al. J Virol. 1994 May;68(5):3145-53. doi: 10.1128/JVI.68.5.3145-3153.1994. J Virol. 1994. PMID: 7908700 Free PMC article.

5

HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers.

Gorse GJ, Patel GB, Belshe RB; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Gorse GJ, et al. AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1175-89. doi: 10.1089/088922201316912781. AIDS Res Hum Retroviruses. 2001. PMID: 11522187 Clinical Trial.

6

Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions.

Arp J, Rovinski B, Sambhara S, Tartaglia J, Dekaban G. Arp J, et al. Viral Immunol. 1999;12(4):281-96. doi: 10.1089/vim.1999.12.281. Viral Immunol. 1999. PMID: 10630788

7

Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.

Wilson SE, Pedersen SL, Kunich JC, Wilkins VL, Mann DL, Mazzara GP, Tartaglia J, Celum CL, Sheppard HW. Wilson SE, et al. AIDS Res Hum Retroviruses. 1998 Jul 20;14(11):925-37. doi: 10.1089/aid.1998.14.925. AIDS Res Hum Retroviruses. 1998. PMID: 9686639

8

Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.

Gómez CE, Nájera JL, Jiménez V, Bieler K, Wild J, Kostic L, Heidari S, Chen M, Frachette MJ, Pantaleo G, Wolf H, Liljeström P, Wagner R, Esteban M. Gómez CE, et al. Vaccine. 2007 Mar 1;25(11):1969-92. doi: 10.1016/j.vaccine.2006.11.051. Epub 2006 Dec 6. Vaccine. 2007. PMID: 17224219

9

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.

Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ. Belshe RB, et al. AIDS. 1998 Dec 24;12(18):2407-15. doi: 10.1097/00002030-199818000-00009. AIDS. 1998. PMID: 9875578 Clinical Trial.

10

Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160.

Fleury B, Janvier G, Pialoux G, Buseyne F, Robertson MN, Tartaglia J, Paoletti E, Kieny MP, Excler JL, Rivière Y. Fleury B, et al. J Infect Dis. 1996 Oct;174(4):734-8. doi: 10.1093/infdis/174.4.734. J Infect Dis. 1996. PMID: 8843210 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

112 results

Results by year